SG11202000115SA - Novel therapeutic enzyme fusion protein and use thereof - Google Patents

Novel therapeutic enzyme fusion protein and use thereof

Info

Publication number
SG11202000115SA
SG11202000115SA SG11202000115SA SG11202000115SA SG11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA SG 11202000115S A SG11202000115S A SG 11202000115SA
Authority
SG
Singapore
Prior art keywords
fusion protein
therapeutic enzyme
novel therapeutic
enzyme fusion
novel
Prior art date
Application number
SG11202000115SA
Other languages
English (en)
Inventor
Yong Ho Heo
Jin Young Kim
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11202000115SA publication Critical patent/SG11202000115SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202000115SA 2017-07-07 2018-07-09 Novel therapeutic enzyme fusion protein and use thereof SG11202000115SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170086594 2017-07-07
PCT/KR2018/007754 WO2019009684A2 (ko) 2017-07-07 2018-07-09 신규 치료학적 효소 융합단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
SG11202000115SA true SG11202000115SA (en) 2020-02-27

Family

ID=64950229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000115SA SG11202000115SA (en) 2017-07-07 2018-07-09 Novel therapeutic enzyme fusion protein and use thereof

Country Status (17)

Country Link
US (1) US20200157172A1 (zh)
EP (1) EP3650539A4 (zh)
JP (2) JP2020530283A (zh)
KR (2) KR102413686B1 (zh)
CN (1) CN111094559A (zh)
AR (1) AR112755A1 (zh)
AU (1) AU2018295994A1 (zh)
BR (1) BR112020000273A2 (zh)
CA (1) CA3069119A1 (zh)
EA (1) EA202090084A1 (zh)
IL (1) IL271837B2 (zh)
MX (1) MX2020000037A (zh)
PH (1) PH12020500054A1 (zh)
SG (1) SG11202000115SA (zh)
TW (1) TWI832818B (zh)
WO (1) WO2019009684A2 (zh)
ZA (1) ZA202000595B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
SG11202005510SA (en) * 2017-12-22 2020-07-29 Hanmi Pharmaceutical Co Ltd Therapeutic enzyme fusion protein having a novel structure and use thereof
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
EP4245311A1 (en) * 2020-11-13 2023-09-20 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease
CN116419759A (zh) * 2020-11-13 2023-07-11 韩美药品株式会社 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0136514B1 (ko) * 1994-12-23 1998-07-01 양승택 공통선 신호장치의 속도정합장치
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
PL206701B1 (pl) * 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
PT1966245E (pt) * 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
US8168185B2 (en) * 2007-01-17 2012-05-01 Merck Serono Sa Process for the purification of anti CD-25 antibodies
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2982689B1 (en) * 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
CN105658664A (zh) * 2013-07-31 2016-06-08 美国安进公司 含有Fc的多肽的稳定化
WO2015066379A2 (en) * 2013-10-30 2015-05-07 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
MX2018004177A (es) * 2015-10-08 2018-09-11 Macrogenics Inc Terapia de combinacion para el tratamiento de cancer.
EP3782639B1 (en) * 2015-12-08 2022-07-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas

Also Published As

Publication number Publication date
PH12020500054A1 (en) 2020-09-21
IL271837B2 (en) 2024-01-01
US20200157172A1 (en) 2020-05-21
BR112020000273A2 (pt) 2020-07-14
EP3650539A4 (en) 2021-08-18
KR102413686B1 (ko) 2022-06-28
KR102556411B1 (ko) 2023-07-18
TWI832818B (zh) 2024-02-21
KR20220098092A (ko) 2022-07-11
AU2018295994A1 (en) 2020-02-06
MX2020000037A (es) 2020-08-06
JP2020530283A (ja) 2020-10-22
JP2023085445A (ja) 2023-06-20
IL271837A (en) 2020-02-27
WO2019009684A2 (ko) 2019-01-10
IL271837B1 (en) 2023-09-01
EP3650539A2 (en) 2020-05-13
TW201906872A (zh) 2019-02-16
CA3069119A1 (en) 2019-01-10
CN111094559A (zh) 2020-05-01
WO2019009684A3 (ko) 2019-03-28
KR20190005803A (ko) 2019-01-16
EA202090084A1 (ru) 2020-06-19
ZA202000595B (en) 2021-04-28
AR112755A1 (es) 2019-12-11

Similar Documents

Publication Publication Date Title
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020006322A (es) Proteinas de fusion il-2 fc modificadas.
EP3788068A4 (en) INTERLEUKIN-15 FUSION PROTEINS AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
WO2018109174A3 (en) Il-11 antibodies
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
EP3749683A4 (en) FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
SG11201806502UA (en) Conjugate of therapeutic enzymes
MY187827A (en) New polypeptide having affinity to pd-l1
EP3626747A4 (en) NEW RECOMBINANT BIFUNCTIONAL FUSION PROTEIN, PROCESS OF PREPARATION AND USE
EP3833391A4 (en) CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
EP3842536A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIER WITH IT
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
EP3976642A4 (en) APOE ANTIBODIES, FUSION PROTEINS AND THEIR USES
SG10201801219VA (en) Anti-HER2 Antibodies
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
MX2020007628A (es) Composiciones y metodos de uso.
EP3604343A4 (en) FUSION PROTEIN, MANUFACTURING METHOD THEREFOR AND USE THEREOF
EP3995508A4 (en) NOVEL MODIFIED IMMUNOGLOBULIN FC FUSION PROTEIN AND USE THEREOF
EP3950720A4 (en) FUSION PROTEIN AND USE THEREOF
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof